Advertisement
Advertisement
ALKS
Alkermes Inc. plc
37.48
USDSponsored
-0.88
-2.29%
May 15, 15:59 UTC -4
Closed
After-Market
37.13
-0.35
-0.93%
ALKS Earnings Reports
Positive Surprise Ratio
ALKS beat 33 of 42 last estimates.
79%
Next Report
Date of Next Report
Jul 27, 2026
Estimate for Q2 26 (Revenue/ EPS)
$467.23M
/-$0.02
Implied change from Q1 26 (Revenue/ EPS)
+18.92%
/-95.00%
Implied change from Q2 25 (Revenue/ EPS)
+19.60%
/-102.99%
Alkermes Inc. plc earnings per share and revenue
On May 05, 2026, ALKS reported earnings of -0.40 USD per share (EPS) for Q1 26, beating the estimate of -0.57 USD, resulting in a 30.87% surprise. Revenue reached 392.91 million, compared to an expected 367.04 million, with a 7.05% difference. The market reacted with a +6.09% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -0.02 USD, with revenue projected to reach 467.23 million USD, implying an decrease of -95.00% EPS, and increase of 18.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$1.07
Actual
-$0.97
Surprise
+9.67%
Invivyd, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.13
Surprise
-73.80%
Autolus Therapeutics plc - ADR
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.26
Actual
-$0.27
Surprise
-2.94%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+217.65%
MiNK Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.78
Actual
-$0.56
Surprise
+27.43%
Elutia Inc. Class A Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
RenovoRx, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
Dare Bioscience, Inc. Common Stock
Report Date
May 14, 2026 For Q1 26
Estimate
-$0.29
Actual
-$0.20
Surprise
+32.39%
Lantern Pharma Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.30%
BioCardia, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-24.78%
FAQ
What were Alkermes Inc. plc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Alkermes Inc. plc reported EPS of -$0.40, beating estimates by 30.87%, and revenue of $392.91M, 7.05% above expectations.
How did the market react to Alkermes Inc. plc's Q1 2026 earnings?
The stock price moved up 6.09%, changed from $34.17 before the earnings release to $36.25 the day after.
When is Alkermes Inc. plc expected to report next?
The next earning report is scheduled for Jul 27, 2026.
What are the forecasts for Alkermes Inc. plc's next earnings report?
Based on 9
analysts, Alkermes Inc. plc is expected to report EPS of -$0.02 and revenue of $467.23M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement